DelveInsight’s “Alopecia Areata Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Alopecia Areata market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alopecia Areata Market Forecast
Some of the key facts of the Alopecia Areata Market Report:
- The Alopecia Areata market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- According to Chantal Bolduc et al., 2018, the prevalence of alopecia areata (AA) in the general population is estimated to be 0.1 — 0.2%. The lifetime risk of developing alopecia areata is estimated to be 1.7%
- As per the National Organization of Rare Disease, alopecia areata is most common among the children and approximately 2.5 million people are suffering from alopecia areata in the United States
- According to the National Alopecia Areata Foundation, approximately 6.8 million people in the United States and 147 million worldwide have or will develop alopecia areata at some point in their lives
- Key Alopecia Areata Companies: Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly, Incyte, Throne Biotechnologies, Legacy Healthcare, Concert Pharmaceuticals, GlaxoSmithKline, Energenesis Biomedical Co., Ltd., Reistone Biopharma, Bristol-Myers Squibb, AnaptysBio, Reistone Biopharma, Novartis, Bioniz, Rigel Pharmaceuticals, Arcutis Biotherapeutics, LEO Pharma, Arena Pharmaceuticals, HCW Biologics, and others
- Key Alopecia Areata Therapies: PF-06651600, Jaktinib, Baricitinib, Stem Cell Educator Therapy, LH-8, CTP-543, Dutasteride, ENERGI-F701, SHR0302, Deucravacitinib, and others
- The Alopecia Areata epidemiology based on gender analyzed that Alopecia Areata affects both males and females equally
- The Alopecia Areata market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alopecia Areata pipeline products will significantly revolutionize the Alopecia Areata market dynamics.
Alopecia Areata Overview
According to the National Alopecia Areata Foundation, Alopecia Areata (AA) is a common autoimmune skin disease, which causes hair loss on the scalp, face, and at times on other areas of the body. The affected hair follicles are attacked by a person’s immune system (white blood cells), which results in seizing of the hair growth stage.
Get a Free sample for the Alopecia Areata Market Report
https://www.delveinsight.com/sample-request/alopecia-areata-market
Alopecia Areata Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Alopecia Areata Epidemiology Segmentation:
The Alopecia Areata market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Alopecia Areata
- Prevalent Cases of Alopecia Areata by severity
- Gender-specific Prevalence of Alopecia Areata
- Diagnosed Cases of Episodic and Chronic Alopecia Areata
Download the report to understand which factors are driving Alopecia Areata epidemiology trends @ Alopecia Areata Epidemiology Forecast
Alopecia Areata Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alopecia Areata market or expected to get launched during the study period. The analysis covers Alopecia Areata market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Alopecia Areata Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Alopecia Areata Therapies and Key Companies
- PF-06651600: Pfizer
- Jaktinib: Suzhou Zelgen Biopharmaceuticals
- Baricitinib: Eli Lilly /Incyte
- Stem Cell Educator Therapy: Throne Biotechnologies
- LH-8: Legacy Healthcare
- CTP-543: Concert Pharmaceuticals
- Baricitinib: Eli Lilly and Company
- Dutasteride: GlaxoSmithKline
- ENERGI-F701: Energenesis Biomedical Co., Ltd.
- SHR0302: Reistone Biopharma
- Deucravacitinib: Bristol-Myers Squibb
Discover more about therapies set to grab major Alopecia Areata market share @ Alopecia Areata Treatment Market
Alopecia Areata Market Strengths
- The major strength of the Alopecia areata market is its robust pipeline with the emergence of several therapies
- Increasing awareness and development to understand the diversity of the disease might improve the diagnosis of Alopecia areata, thereby resulting in a lucrative market opportunity
Alopecia Areata Market Opportunities
- Several organizations are actively working to provide information and awareness of such rare and devastating disorder
- The current treatment options only focus on palliative treatment rather than cure, which opens a platform of new therapies to boost the market of Alopecia areata
Scope of the Alopecia Areata Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Alopecia Areata Companies: Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly, Incyte, Throne Biotechnologies, Legacy Healthcare, Concert Pharmaceuticals, GlaxoSmithKline, Energenesis Biomedical Co., Ltd., Reistone Biopharma, Bristol-Myers Squibb, AnaptysBio, Reistone Biopharma, Novartis, Bioniz, Rigel Pharmaceuticals, Arcutis Biotherapeutics, LEO Pharma, Arena Pharmaceuticals, HCW Biologics, and others
- Key Alopecia Areata Therapies: PF-06651600, Jaktinib, Baricitinib, Stem Cell Educator Therapy, LH-8, CTP-543, Dutasteride, ENERGI-F701, SHR0302, Deucravacitinib, and others
- Alopecia Areata Therapeutic Assessment: Alopecia Areata current marketed and Alopecia Areata emerging therapies
- Alopecia Areata Market Dynamics: Alopecia Areata market drivers and Alopecia Areata market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Alopecia Areata Unmet Needs, KOL’s views, Analyst’s views, Alopecia Areata Market Access and Reimbursement
To know more about Alopecia Areata companies working in the treatment market, visit @ Alopecia Areata Clinical Trials and Therapeutic Assessment
Table of Contents
1. Alopecia Areata Market Report Introduction
2. Executive Summary for Alopecia Areata
3. SWOT analysis of Alopecia Areata
4. Alopecia Areata Patient Share (%) Overview at a Glance
5. Alopecia Areata Market Overview at a Glance
6. Alopecia Areata Disease Background and Overview
7. Alopecia Areata Epidemiology and Patient Population
8. Country-Specific Patient Population of Alopecia Areata
9. Alopecia Areata Current Treatment and Medical Practices
10. Alopecia Areata Unmet Needs
11. Alopecia Areata Emerging Therapies
12. Alopecia Areata Market Outlook
13. Country-Wise Alopecia Areata Market Analysis (2019–2032)
14. Alopecia Areata Market Access and Reimbursement of Therapies
15. Alopecia Areata Market Drivers
16. Alopecia Areata Market Barriers
17. Alopecia Areata Appendix
18. Alopecia Areata Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services